IP Library Granted Patent US 8,921,366
Granted Patent B2
US 8,921,366 · App. 13/846,119 · Granted Dec 30, 2014

Substituted triazolo-pyridazine derivatives

Inventor: Scott L. Harbeson (Cambridge, MA)
Assignee: Concert Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,366
App. No.
13/846,119
Granted
Dec 30, 2014
Kind
B2
Abstract

This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA-A receptor antagonist and/or a α2, α3 and α5 GABA-A receptor agonist.

Claims (19)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is CH 3 or CD 3 ;

R 2 is —C(CD 3 ) 3 ;

Y 1a and Y 1b are the same and are selected from hydrogen or deuterium;

Y 2 is hydrogen or deuterium; and

the compound has at least 90% deuterium incorporation at each position designated as deuterium.

2. The compound of claim 1 , selected from:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound has at least 95% deuterium incorporation at each position designated as deuterium.

4. The compound of claim 1 , wherein the compound has at least 97% deuterium incorporation at each position designated as deuterium.

5. The compound of claim 1 , wherein any atom not designated as deuterium is present at its natural isotopic abundance.

6. A pyrogen-free pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

7. A method of:

a. inhibiting the α-1 subtype of the GABA-A receptor in a cell; or

b. activating one or more of the α2, α3 and α5 subtypes of the GABA-A receptor in a cell,

the method comprising contacting the cell with a compound of claim 1 .

8. A method of treating a patient suffering from a disease or condition selected from neuropathic pain, inflammatory pain, and migraine pain, comprising the step of administering to the patient in need thereof a composition of claim 6 .

9. A method of treating a patient suffering from anxiety or convulsions, the method comprising the step of administering to the patient in need thereof a pharmaceutical composition of claim 6 .

Assignments (2)
MERGER Recorded Aug 2, 2023
From: CONCERT PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 064465/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2014
From: HARBESON, SCOTT
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 034222/0667 →
Continuity (4)
Continuation 13174662 · Jun 30, 2011
Continuation 12550346 · Aug 28, 2009
Provisional Application 61093293 · Aug 29, 2008
Related Publication 20130225590A1 · Aug 29, 2013